Innovative model highlights potential platform to develop novel therapies

Researchers at Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine pioneered a new model that offers a potential platform for developing novel therapies to treat Alpha Thalassemia (AT), a severe blood disorder. The findings were published in the journal Blood.

Thousands of children are born with AT every year, especially in South-East Asia, India, the Middle East, and the Mediterranean basin. When functioning normally, the genetic trait may provide protection against malaria and result in mild anemia. However, when both parents are carriers of faulty genes, children face an elevated risk of severe AT. In the most severe cases, the disease can be fatal without in utero intervention. Children with severe AT often require ongoing blood transfusions and extensive medical care.

“New treatments for blood disorders have experienced remarkable success in recent years, particularly for conditions like beta thalassemia and sickle cell disease. However, despite representing a growing healthcare challenge, Alpha Thalassemia has drawn significantly less attention,” said senior author Stefano Rivella, PhD, a research faculty member in the Division of Hematology at CHOP. “Our hope is that generating animal models will provide a powerful tool for future research, along with avenues of investigation for human patients.”

Allogeneic bone marrow transplantation (BMT) is currently the only available therapeutic option for patients with severe AT, and that method also requires an appropriate donor. Additionally, until now, research into therapeutic advancements for AT was limited due in part to the challenge of creating adult mouse models with this disease.

In this study, researchers designed an innovative model by deleting alpha globin genes in adult mice using a lipid nanoparticle (LNP) embedded within mRNA that induced the deletion of the alpha globin genes. This led to the production of faulty red blood cells (RBC) with abnormal hemoglobin, called HbH, that binds oxygen tightly, preventing its delivery to tissues and causing paradoxical hypoxia. The targeted LNP platform technology was previously established by Hamideh Parhiz, PharmD, PhD, a co-senior study author and Assistant Professor of Medicine at Penn Medicine. Her team also generated targeted LNP to hematopoietic stem cells encapsulating mRNA for the current study.

Once the alpha globin genes were deleted, the mice experienced decreased oxygen levels comparable to individuals with severe AT. The mice were flooded with RBC that couldn’t transport oxygen, posing an extreme health threat. The researchers confirmed that this model can now be applied to test novel or genetic therapies in human patients to improve their clinical care.

Rivella, along with members of his lab, including, Laura Breda, PhD, Maxwell Chapell, PhD, Lucas Tricoli, PhD, and Amaliris Guerra, PhD, developed a method to perform gene complementation to repair the defective genetic traits via hematopoietic stem cell modification and transplantation. The researchers used a lentiviral vector expressing human alpha globin, named ALS20aI, and found it produced high levels of human alpha globin in the mice, sustaining them and boosting normal hemoglobin production. They also noted that ongoing bone marrow transplantation resulted in the continued expression of human alpha globin, indicating that ALS20aI effectively modify stem cells in the blood to provide long-lasting corrections to AT.

“This innovative approach represents a much-needed step forward in the treatment of Alpha Thalassemia,” said Rivella. “We look forward to further research and the promise of improved patient outcomes with fewer complications over time.”

The authors would like to acknowledge the Pathology Core Laboratory at CHOP’s Research Institute for providing histological, immunohistochemical, and imaging services. The research was funded by CHOP’s Research Institute’s Bridge to Faculty Program (A.G.), the National Heart, Lung and Blood Institute grant 5K99HL156060-03 (K.G.), the National Heart, Lung, and Blood Institute grant 5R61HL156158-02(O.A.), and SARG-NKUA Code 12260 (A.K.), and NIH grants R01 CA241762 (to F.D.B). The authors wish to acknowledge that CD34 cells were supplied by Fred Hutch NIDDK-CCEH Cell Processing Core, which is funded through NIDDK Grant U54 DK106829.

Rivella, et. al. “Use of HSC Targeted LNP to Generate a Mouse Model of Lethal α-Thalassemia and Treatment via Lentiviral Gene Therapy.” Blood. Online July 1, 2024. DOI:10.1182/blood.2023023349.

 

About Children’s Hospital of Philadelphia:

A non-profit, charitable organization, Children’s Hospital of Philadelphia was founded in 1855 as the nation’s first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey, as well as the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia. In addition, its unique family-centered care and public service programs have brought Children’s Hospital of Philadelphia recognition as a leading advocate for children and adolescents.

Source: https://www.prnewswire.com/news-releases/researchers-at-childrens-hospital-of-philadelphia-find-lentiviral-gene-transfer-improves-human-alpha-globin-production-for-the-treatment-of-alpha-thalassemia-302187356.html
GMP mRNA
Check out our mRNA service to expedite your vaccine research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Future Of Gamma Delta T Cell Therapies

Gamma delta T cell-based immunotherapies have emerged as a promising frontier in cancer treatment and beyond, building on the success of chimeric antigen receptor T-cell (CAR T cell) therapy and expanding on the potential of the immune system as a therapeutic...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE